Articles tagged with Cancer
A new study reveals that cancer cells may begin escaping therapy much earlier, triggered by a stress response that drives them into a temporary drug-tolerant state. Researchers identified an early molecular trigger: NF-κB, which acts as a regulator of cellular stress and survival.
The study reveals that metabolic dysfunction-associated steatotic liver disease (MASLD) is emerging as a major contributor to liver cancer worldwide and in China. Researchers call for integrated global prevention and early detection strategies to address this growing burden.
Oncology services are often excluded from emergency health priorities, resulting in delayed diagnosis and treatment interruptions. Vulnerable populations, including women and children, face advanced disease stages due to delays in care.
Research from Alberta reveals that survivors of adolescent and young adult cancers are at double the risk of developing most types of later cancers. Lymphoma and breast cancer were found to be the most common subsequent cancers after an initial diagnosis, with breast, colorectal, and lung cancers making up 43% of cases.
The Marlene and Stewart Greenebaum Family Foundation donated $5.5 million to the University of Maryland Greenebaum Comprehensive Cancer Center to fund groundbreaking scientific research and compassionate cancer care. The funds will support innovative treatments, including immunotherapies, and strengthen support for cancer survivors.
The study projects that cancer rates in Canada will be high in 2026, with declines seen in some cancers like colorectal and leukemia. However, death rates from pancreatic cancer are increasing.
A study of over 600,000 people found that early weight gain is associated with a higher risk of dying from various diseases, particularly cardiovascular disease and type 2 diabetes. Weight gain during adulthood also increases the risk of premature death, especially for those who develop obesity at a younger age.
Researchers at ITQB NOVA and IPOLFG are developing a new project called BRIDGE to improve diagnosis and treatment of aggressive breast cancers. They aim to find new biomarkers to monitor cancer evolution and tailor treatment to individual patient needs.
A new study maps how rare mixed tumors evolve into hybrid cell states and immune-protected neighborhoods, pointing to new ways to detect and treat combined small-cell lung cancer. The findings reveal that these tumors do not arise from two separate cancers but rather from a single ancestral cell that evolves over time.
Several open-source AI models consistently produced summaries that were more comprehensive than physician-written versions, particularly in capturing molecular and genetic findings. The study found that Llama 3.1 and DeepSeek performed best among the six evaluated models.
Nancy L. Lewis, MD, MBS, FACP, a renowned biomedical researcher and clinical trials expert, has been appointed as the new Chief Scientific Officer of the National Comprehensive Cancer Network (NCCN). She will oversee NCCN's programs to advance clinical trials and improve cancer care outcomes globally.
UCLA investigators present new research on targeted drug delivery for colorectal cancer, COVID-19's impact on breast cancer outcomes, and AI in cancer diagnosis. These studies offer insights into overcoming drug resistance, enhancing immune responses, and improving outcomes for patients with difficult-to-treat cancers.
Researchers generated a comprehensive view of DNA methylation abnormalities in human MDS HSCs, uncovering a novel TET2-GFI1 axis that suppresses malignant transformation. The study identifies key hematopoietic regulators and provides a panoramic view of DNA methylation disruption in MDS.
Researchers found that blocking clusterin, a molecule linked to stress and tumor growth, slows tumor growth signals and makes the cancer more responsive to cisplatin. The study's findings offer a possible strategy for treating cervical gastric-type adenocarcinoma, one of the most aggressive non-HPV associated cervical adenocarcinomas.
The American Society of Hematology and the International Society on Thrombosis and Haemostasis have released comprehensive guidelines for anticoagulant prophylaxis in non-cardiac pediatric patients at risk of venous thromboembolism. The guidelines outline best practices for preventing life-threatening complications in children.
The European Association of Nuclear Medicine (EANM) has joined the EMUC26 congress to promote nuclear medicine expertise in urological cancers. The event will bring together healthcare professionals from various disciplines to discuss current practices and emerging innovations.
A study published in Cell Reports reveals a two-phase model explaining the origin of childhood B-ALL, involving hyperdiploidy and subsequent malignant transformation. Hyperdiploidy causes chromosomal instability, delaying cell differentiation and allowing rare clones to persist without triggering leukaemia.
A new study found that maintaining a healthy weight from early adulthood is associated with lower risks of premature death from various diseases. Excess weight at 25 years old has lasting effects on mortality risk, independent of subsequent weight changes.
Researchers from St. Jude Children's Research Hospital discovered the gene-regulatory protein PHIP as a critical vulnerability in cancers driven by broad SWI/SNF inactivation. PHIP's loss disrupts cancer growth and cooperates with SWI/SNF to activate transcription, providing evidence for therapeutic development of PHIP-inhibiting drugs.
Advanced or metastatic cancers often go without tumor genomic testing, with those from low-income backgrounds facing longer wait times. JAMA Network Open highlights the need for targeted healthcare policies to bridge these gaps.
The NCCN Advocacy Academy connects oncology professionals with policymakers to drive evidence-based cancer policy. The program aims to cultivate policy leadership skills among emerging scientists and care providers.
Researchers discovered that neuronal nitric oxide synthase drives neuroblastoma through the mTOR signaling cascade. Treating cancer cells with a selective inhibitor called BA-101 collapsed tumor growth in mice with striking force, and silencing the nNOS gene also led to significant results.
A new study offers a powerful approach to personalized bladder cancer care using a non-invasive urine test. The test can detect minimal residual disease while accounting for mutations present in normal urothelium, allowing clinicians to distinguish between patients who benefit from additional therapy and those who don't.
Researchers studied cancer deaths in nearly 3,000 US counties from 1981-2019, finding urban and affluent counties experienced significant declines. However, rural areas often had lower rates of improvement, with some cities like New York City showing notable reductions in lung cancer mortality.
A new active agent enables photodynamic therapy to target cancer cells without relying on oxygen levels. The agent's interaction with intracellular iron triggers a rapid electron transfer process, generating highly reactive hydroxyl radicals that kill cancer cells.
Researchers found that an extract of turmeric and ginger helps bone implants bond strongly while killing bacteria and cancer cells. The extract roughly doubled bone bonding within six weeks around the implant site, killed more than 90% of bacteria on implant surfaces, and sharply reduced cancer-causing cells.
Dr. Ulrich Steidl, MD, Ph.D., has been appointed as the director of the prestigious Montefiore Einstein Comprehensive Cancer Center and vice president of cancer medicine at Montefiore Einstein. With extensive experience in blood cancer and stem cell research, Dr. Steidl aims to advance innovative science that improves lives worldwide.
Researchers have identified a fundamental mechanism underlying Sanfilippo syndrome, a common form of childhood dementia. Chronic overactivity in the brain appears to be a key contributor to cognitive deterioration in children with the condition. The study's findings represent significant progress and may lead to personalized treatment ...
Researchers have created a detailed molecular map of the thromboxane A2 receptor, which could lead to the development of safer and more effective therapies targeting this clinically important signalling system. The study reveals an unusual activation switch and provides insights into how signalling molecules interact with the receptor.
Researchers at Umeå University have discovered a key protein that helps cancer cells survive treatment by blocking apoptosis. The study provides a deeper understanding of how proteins interact within the cell, which could lead to new cancer therapies targeting Bcl-2 and its protective function.
Researchers reveal that immune system's T cells travel to the prostate to provide long-term protection against infections. Harnessing these disease-fighting cells could lead to new therapies for prostate cancer and inflammatory conditions.
The Alliance for Clinical Trials in Oncology is enrolling adolescent and young adult cancer patients in various trials, including genetic services and treatment studies. These trials aim to address longstanding gaps in care and improve outcomes for AYAs with cancer.
A study by Princeton University researchers found that high-fat diets contribute to aggressive breast cancer growth, with tumors fed fatty acids forming hollow appendages. The team's 3D model showed that a ketogenic diet did not provide the expected benefits for this type of cancer.
A new blood-based biomarker has been discovered to help identify individuals at higher risk of developing cancer in people with Lynch Syndrome. The biomarker uses immune signatures detected in blood samples to provide unique characteristics that can detect cancer risk, allowing for early detection and personalized surveillance.
Salk Institute researchers have developed a new biological platform for studying mitochondrial DNA in human physiology, adaptation, and therapeutic development. The platform allows scientists to investigate mitochondrial DNA variation in health and disease, enabling therapeutic innovation for mitochondrial disorders.
A new study found that metformin raises levels of N-lactoyl-phenylalanine, a molecule tied to energy balance and weight control, in men with prostate cancer. This finding suggests metformin could help counter metabolic strain caused by hormone therapy, which often limits physical activity.
Researchers at the University of Mississippi have developed a new method for delivering cancer-fighting drugs using 3D-printed nanocarriers, which can target specific tumor sites and minimize side effects. This innovative approach has shown promising results in killing cancer cells and reducing the impact of traditional chemotherapy.
A new, cost-effective blood test detects liver, lung, ovarian, stomach cancers, and various non-cancer conditions by analyzing DNA fragments in the bloodstream. The test achieved high accuracy rates for multi-cancer detection and tissue-of-origin identification.
The COCOON trial found that a structured dermatologic prophylaxis regimen reduced moderate-to-severe dermatologic adverse events by half, with fewer grade ≥3 events and treatment discontinuations. This approach could improve tolerability and maintain dose intensity for EGFR-mutant non-small cell lung cancer patients.
A Waseda University research team developed a nanotube membrane-based injector to directly and reliably manipulate the cytoplasmic composition of living cells. The system successfully transferred cytoplasmic contents, including mitochondria, into target cells with high efficiency and minimal damage.
Renowned cancer scientist Thales Papagiannakopoulos is joining the Salk Institute as a professor, bringing expertise in cancer metabolism and immunology. He will collaborate with colleagues to uncover how tumors interact with the nervous system and develop new therapeutic strategies.
Fábio Rosa's research has enabled genetic reprogramming of various cancer cell types to activate the immune system and bring about their own destruction. His approach uses tools from gene therapy to generate rare and functionally specialized immune cells that trigger powerful anti-tumor responses.
Researchers reveal that high levels of hypoxia-inducible factor-2 (HIF-2) in pancreatic tumor microenvironment protects cells from ferroptosis, a promising target for therapy. The study identifies key biochemical pathways activated by HIF-2 to limit ferroptotic cell death.
Researchers developed first-in-class dual HIF inhibitors that, when combined with immunotherapy, can completely eliminate breast, colorectal, melanoma, and prostate tumors in mice. The drugs target HIF-1/2 transcription factors, which are key regulators of cancer progression.
Scientists discovered how tumors disable dendritic cell function by decreasing their mitochondrial fitness, leading to weakened immune defenses against cancer. Restoring mitochondrial function in dendritic cells improves antitumor immune responses and enhances immunotherapeutic efficacy.
A study reveals CHKA and EGFR cooperate to activate the MAPK pathway, driving glioma progression. CHKA knockdown suppresses tumor growth, while EGFR overexpression rescues this effect.
Researchers identified DMBT1 as a key target of Lentinus edodes-derived β-glucan in inhibiting cervical cancer progression. The compound's anti-cancer activity was shown to be closely correlated with DMBT1 expression levels, suggesting its potential as a prognostic marker or therapeutic target.
The NCCN Foundation recognizes five young investigators for their promising research on cancer innovation, providing $100,000 grants to advance their work and strengthen the pipeline for cancer success.
Researchers created a CRISPR-based tool to pinpoint genes the cancer turns off, restoring a key cancer-fighting gene in leukemia. The study found that blocking KDM4 enzymes can regain expression of the tumor-suppressor gene ZBTB7A, reducing leukemia burden while leaving normal blood formation largely unaffected.
Researchers at University of Liège develop mouse model to study Stard7's role in intestinal cancers, revealing protein's dual effects on tumour development. In some cases, Stard7 deficiency reduces tumour growth, while in others it accelerates it.
Researchers developed a blood-based test that analyzes circulating tumor HPV DNA to inform personalized treatment strategies for HPV-associated throat cancer. The study found that ctDNA levels change before and after surgery, influenced by tumor biology and kidney function.
According to a new study published in The Lancet, childhood cancer is the eighth-leading cause of death among children worldwide. Researchers found that over 377,000 new cases and 144,000 deaths occurred in 2023, with most cases in low- and middle-income countries.
Researchers found that targeting MD2 could reduce tumor growth in a mouse model of prostate cancer bone metastasis. High MD2 expression was associated with metastasis, immune suppression, and increased resistance to PARP inhibitor therapy.
The NCCN 2026 Annual Conference emphasized the need for holistic care for adolescents and young adults with cancer, highlighting unique challenges and the importance of supportive services. The conference also addressed global cancer care realities and future strategies, emphasizing the need for collaboration and investment to address ...
A phase 1/2 clinical study found that pralsetinib improved durable responses with manageable safety profiles in patients with advanced or metastatic RET fusion-positive non-small cell lung cancer. The overall response rate was 78% and median duration of response was longer in patients with the CCDC6-RET fusion gene.
A study published in Nature Health reveals a strong link between pesticide exposure and the risk of developing certain cancers. The research shows that pesticide exposure increases the risk of cancer by 150% in areas with high levels of pollution, and highlights early biological effects before cancer develops.
Researchers have developed a potential non-invasive treatment for melanoma using a stretchy, heat-activated skin patch that releases copper ions to kill cancer cells. The patch reduced melanoma lesions by 97% in a preliminary animal study, with no damage to surrounding tissue.
Mohamed Abou-el-Enein, a USC physician-scientist, has received the Outstanding New Investigator Award and Best of Molecular Therapy Award from the American Society of Gene + Cell Therapy. His work focuses on translating scientific discoveries into clinical applications, with a particular emphasis on cell therapies.
A team from UNIGE has created a molecular system that distinguishes and neutralises cancer cells with unprecedented precision, paving the way for autonomous, self-regulating drugs. The technology uses synthetic DNA strands to deliver potent drugs only where they are needed, reducing damage to healthy tissue.